A legitimate CJC-1295 program is defined by what happens before the first injection: a baseline IGF-1 draw and a licensed prescriber. Any program that moves from a checkout page to a shipped vial without lab work has skipped the step that makes the therapy measurable.
A real CJC-1295 peptide therapy program is built around three things: a baseline IGF-1 before anything is prescribed, a licensed prescriber working from that lab, and a compounding pharmacy you can name. Everything else follows from those. This guide covers what the therapy can and cannot do, what the human data actually support, and the red flags that separate a clinical program from a storefront selling vials.
- CJC-1295 is a long-acting GHRH analog that raises the body's own GH and IGF-1 rather than delivering GH directly [3]
- A single dose raised GH 2 to 10-fold for 6 days or more and IGF-1 for 9 to 11 days, with a half-life of 5.8 to 8.1 days [1]
- A legitimate program requires a baseline IGF-1 before prescribing; skipping it is the clearest red flag
- The pharmacy should be a named 503A or 503B facility, and compounded peptides are not FDA-verified for quality before sale [6]
- The FDA has identified serious adverse events for CJC-1295 and it is not an FDA-approved drug [4]
- Retest IGF-1 at 90 days; a result above the age-adjusted range is a reason to cut the dose
What CJC-1295 Therapy Actually Does
CJC-1295 is a long-acting GHRH analog. It binds the GHRH receptor on the pituitary and prompts the gland to release more of its own growth hormone [3]. It does not deliver GH. That upstream mechanism is the reason the pituitary keeps its own feedback control rather than being overridden the way it is by injected HGH.
The long duration is the signature. In healthy adults, a single dose raised mean plasma GH 2 to 10-fold for 6 days or more and IGF-1 1.5 to 3-fold for 9 to 11 days, and repeated dosing kept IGF-1 above baseline for up to 28 days [1]. The estimated half-life is 5.8 to 8.1 days [1]. That is why CJC-1295 is dosed far less often than sermorelin, which clears in minutes.
Realistic Expectations
The measurable effect of CJC-1295 is a sustained rise in IGF-1. What that translates to in a person is where the honesty has to come in, because the human evidence stops at the biomarker. There is no long-term trial showing body-composition outcomes for CJC-1295, and the only registered patient trial was terminated in 2006 [1].
Set expectations against the GHRH-analog class rather than the marketing. Sleep quality is the first thing most people report, within the first few weeks. Body-composition changes, when they come, develop over a protocol measured in months, not weeks, and depend on training and protein intake as much as on the peptide. CJC-1295 is not a weight-loss drug, and a program promising rapid fat loss is describing something the evidence does not support.
IGF-1 is the marker that tells you the therapy is working. A retest around 90 days shows whether the dose moved IGF-1 into the target range. A number above the age-adjusted range is a signal to reduce the dose, not a sign the therapy is working harder.
What a Legitimate Program Looks Like
The structure is the same for every GH-axis peptide, and CJC-1295 does not get an exception because it is convenient. A clinical program runs in a fixed order.
- A baseline IGF-1 draw before anything is prescribed, so there is a real starting number
- An evaluation by a licensed prescriber who reviews the labs and your history, not a checkout questionnaire
- A named compounding pharmacy, 503A or 503B, with a Certificate of Analysis available for the lot
- A defined dose and schedule set against your labs rather than a fixed template
- An IGF-1 retest around 90 days, with the dose adjusted down if the result is above range
- Ongoing follow-up, including glucose monitoring for anyone with prediabetes or diabetes
The pharmacy tier is worth understanding. A 503B outsourcing facility works under current good manufacturing practice requirements that a 503A pharmacy does not, and compounded drugs of either type are not verified by the FDA for safety, effectiveness, or quality before marketing [6]. Knowing which pharmacy fills your prescription is a reasonable question, and a program that will not answer it is telling you something.
The Red Flags
The warning signs are consistent, and most of them are visible before you pay. Any one of these is a reason to look elsewhere.
- No baseline IGF-1 required before prescribing, the single clearest red flag
- Prescription issued from a questionnaire with no licensed prescriber you can identify
- The pharmacy is unnamed, or no Certificate of Analysis is available for the lot
- Pricing revealed only after a consultation call
- Claims of rapid fat loss or specific pound-for-pound results the evidence does not support
- No plan for a 90-day IGF-1 retest or dose adjustment
The safety context belongs here too. FDA states it has identified serious adverse events for CJC-1295, including increased heart rate and a systemic vasodilatory reaction, and that clinical data are limited [4]. That is exactly why a prescriber and lab monitoring are not optional extras on this peptide. Anyone subject to anti-doping testing should also know CJC-1295 is prohibited in sport at all times [5].
The Honest Verdict
CJC-1295 therapy is reasonable to consider for someone with low or low-normal IGF-1 who wants less frequent dosing than sermorelin allows. The trade is convenience against a thinner long-term evidence base and a documented FDA safety signal. Neither of those makes it a bad choice; both make the clinical structure around it more important, not less.
Judge a program by whether it earns the prescription before it fills it. Baseline labs, a real prescriber, a named pharmacy, and a 90-day retest are the difference between therapy and a transaction. A program that has those is one you can measure. A program that skips them is selling a vial.
The whole difference between therapy and a transaction is whether a program tests before it prescribes. SystemLabs tests IGF-1 before prescribing and formulates CJC-1295 on clinical indication, so the dose is set against your labs and retested at 90 days rather than shipped from a checkout page.
Frequently Asked Questions
What is CJC-1295 peptide therapy?
It is a program that uses CJC-1295, a long-acting GHRH analog, to raise the body's own growth hormone and IGF-1 rather than delivering GH directly [3]. A legitimate program pairs the peptide with a baseline IGF-1 draw, a licensed prescriber, a named 503A or 503B pharmacy, and a 90-day retest.
How much does CJC-1295 therapy raise IGF-1?
In healthy adults, a single dose raised IGF-1 roughly 1.5 to 3-fold for 9 to 11 days, and repeated dosing kept it above baseline for up to 28 days [1]. The exact rise depends on your starting level and dose, which is why a baseline draw and a 90-day retest are how the therapy is measured.
How do I know if a CJC-1295 program is legitimate?
The clearest test is whether it requires a baseline IGF-1 before prescribing and runs through a licensed prescriber you can identify. Add a named 503A or 503B pharmacy with a Certificate of Analysis, a defined dose set against your labs, and a 90-day retest. A program that skips the baseline lab or hides its pharmacy is the one to avoid.
Is CJC-1295 therapy FDA approved?
No. CJC-1295 is not an FDA-approved drug and is dispensed as a compounded preparation, which the FDA does not verify for quality before sale [6]. The FDA also lists it among bulk substances that may present significant safety risks, with serious adverse events identified [4], which is why prescriber oversight and lab monitoring matter.
How often is CJC-1295 injected in a therapy program?
Far less often than sermorelin, because its half-life is 5.8 to 8.1 days and its effect on IGF-1 lasts many days after a single dose [1]. The specific schedule should come from a prescriber working from your IGF-1, not from a fixed template.
What results can I expect from CJC-1295 therapy?
The measurable result is a sustained rise in IGF-1; beyond that, sleep improvement is the most commonly reported early change, with body-composition changes developing over months alongside training and adequate protein. There is no long-term human trial of body-composition outcomes for CJC-1295, so a program promising rapid fat loss is overstating the evidence [1].
References
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults Journal of Clinical Endocrinology & Metabolism, 2006. PMID: 16352683. https://pubmed.ncbi.nlm.nih.gov/16352683/
- Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog Journal of Clinical Endocrinology & Metabolism, 2006. PMID: 17018654. https://pubmed.ncbi.nlm.nih.gov/17018654/
- Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog Endocrinology, 2005. PMID: 15817669. https://pubmed.ncbi.nlm.nih.gov/15817669/
- Certain bulk drug substances for use in compounding that may present significant safety risks FDA.gov, Human Drug Compounding, 2026. Content current as of 04/22/2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- The 2026 Prohibited List: International Standard, section S2.2.4 growth hormone releasing factors World Anti-Doping Agency, 2026. WADA 2026 Prohibited List. https://www.wada-ama.org/en/resources/2026-prohibited-list
- Compounding and the FDA: questions and answers FDA.gov, Human Drug Compounding, 2025. Content current as of 09/16/2025. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
